Preclinical study reveals marked glycolytic vulnerability driven by mitochondrial dysfunction in triple-negative breast cancer cells, suggesting a viable metabolic therapeutic target.
Our study shows that TNBC cells have profound metabolic alterations characterized by decreased mitochondrial respiration and increased glycolysis. Due to their impaired mitochondrial function, TNBC cells are highly sensitive to glycolytic inhibition, suggesting that such metabolic intervention may be an effective therapeutic strategy for this subtype of breast cancer cells.
No takes yet. Share an insight, caveat, or question.
Pelicano et al. (2014) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: